Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs in the acute care environment. The company is headquartered in Lexington, Massachusetts. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first IV antibiotic from a class of antiinfectives called lipopeptides. Cubist employs 409 people. The company's total net revenues increased 61% to $194.7 million in 2006 from $120.6 million in 2005.
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs.
Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel antiinfectives for use in hospitals and other acute care environments.
Cubist completed its initial public offering (IPO) in 1996, and shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, we resumed human trials with daptomycin in IV form and it was approved by the FDA as CUBICIN (daptomycin for injection) and launched in the U.S. in 2003. CUBICIN has to date experienced the most successful antibiotic launch in U.S. history, on a dollar sales basis. In 2005, Cubist submitted a sNDA seeking an expanded label for CUBICIN based on results of the Company's landmark Phase 3 trial studying the treatment of S.aureus bloodstream infections, including infective endocarditis. Following the positive recommendations of the Anti-infective Drugs Advisory Committee in March 2006, the FDA approved an expanded U.S. label for CUBICIN on May 25, 2006. For information on the expanded label please visit www.cubicin.com
Products & Pipeline
The promise of Cubist Pharmaceuticals is based on both a current product, CUBICIN® (daptomycin for injection), which represents the most successful IV antibiotic launch, in dollar terms, in U.S. history, as well as on internal discovery and external sourcing of acute care drug candidates.
Cubist is continuing research to help optimize knowledge about the utility and advantages of CUBICIN in the infectious disease armamentarium. CUBICIN development includes a Phase 2 high dose short duration (10 mg/kg for 4 days) cSSSI study and a Phase 2 comparative dose (6 and 8 mg/kg) study in prosthetic joint infections. Cubist believes CUBICIN will continue growing (to greater than $750 Million annually in the U.S. alone) with its current labeled indications and has not yet made decisions on the appropriateness of additional registration (Phase 3) studies.
The company has a growing early stage pipeline of programs which can leverage Cubist's scientific, clinical and regulatory expertise as well as its proven acute care commercial organization. The company's intent is to continue to build this pipeline using internal discovery, research collaborations, in-licensing and acquisition to maximize the opportunity for a flow of IND filings in the years ahead, thus enabling continued revenue growth beyond CUBICIN, which has patent protection in the U.S. through 2019. Current preclinical programs include research focused on: Gram positive infections including infections in the lung and CDAD; Gram negative infections; and candidates emerging from Natural Products screening.
Cubist Pharmaceuticals and Santa Clara-based Ilypsa have entered into a research collaboration to develop a non-antibiotic therapy for Clostridium difficile associated diarrhea (CDAD).
Cubist believes CUBICIN will continue growing (to greater than $750 Million annually in the U.S. alone
***Technical Charts With Annotations For CBST:***
Yahoo Finance news and quotes for CBST:
StockCharts Delayed StockCharts: